Trial for new bleeding disorder pill withdrawn before starting
Disease control
Terminated
This was an early-stage study to test the safety and find the right dose of a new oral drug called HMPL-523 for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing a risk of bleeding. The study was designed to enroll adults wh…
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC